A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment
- PMID: 26567470
- DOI: 10.3109/15563650.2015.1110590
A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment
Abstract
Context: Synthetic cannabinoids (SCs) such as "Spice", "K2", etc. are widely available via the internet despite increasing legal restrictions. Currently, the prevalence of use is typically low in the general community (<1%) although it is higher among students and some niche groups subject to drug testing. Early evidence suggests that adverse outcomes associated with the use of SCs may be more prevalent and severe than those arising from cannabis consumption.
Objectives: To identify systematically the scientific reports of adverse events associated with the consumption of SCs in the medical literature and poison centre data.
Method: We searched online databases (Medline, PsycInfo, Embase, Google Scholar and Pubmed) and manually searched reference lists up to December 2014. To be eligible for inclusion, data had to be from hospital, emergency department, drug rehabilitation services or poison centre records of adverse events involving SCs and included both self-reported and/or analytically confirmed consumption.
Results: From 256 reports, we identified 106 eligible studies including 37 conference abstracts on about 4000 cases involving at least 26 deaths. Major complications include cardiovascular events (myocardial infarction, ischemic stroke and emboli), acute kidney injury (AKI), generalized tonic-clonic seizures, psychiatric presentations (including first episode psychosis, paranoia, self-harm/suicide ideation) and hyperemesis. However, most presentations were not serious, typically involved young males with tachycardia (≈ 37-77%), agitation (≈ 16-41%) and nausea (≈ 13-94%) requiring only symptomatic care with a length of stay of less than 8 hours.
Conclusions: SCs most frequently result in tachycardia, agitation and nausea. These symptoms typically resolve with symptomatic care, including intravenous fluids, benzodiazepines and anti-emetics, and may not require inpatient care. Severe adverse events (stroke, seizure, myocardial infarction, rhabdomyolysis, AKI, psychosis and hyperemesis) and associated deaths manifest less commonly. Precise estimates of their incidence are difficult to calculate due to the lack of widely available, rapid laboratory confirmation, the variety of SC compounds and the unknown number of exposed individuals. Long-term consequences of SCs use are currently unknown.
Keywords: Emergency medical services; drug overdose; drug-related side effects and adverse reactions; mental disorders; street drugs.
Similar articles
-
Marijuana use and acute myocardial infarction: A systematic review of published cases in the literature.Trends Cardiovasc Med. 2020 Jul;30(5):298-307. doi: 10.1016/j.tcm.2019.08.003. Epub 2019 Aug 14. Trends Cardiovasc Med. 2020. PMID: 31439383
-
The Synthetic Cannabinoids Phenomenon.Curr Pharm Des. 2016;22(42):6420-6425. doi: 10.2174/1381612822666160919093450. Curr Pharm Des. 2016. PMID: 27655416 Review.
-
Do police arrestees substitute legal highs for other drugs?Int J Drug Policy. 2016 May;31:74-9. doi: 10.1016/j.drugpo.2016.01.006. Epub 2016 Jan 18. Int J Drug Policy. 2016. PMID: 26948501
-
Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs.Clin Toxicol (Phila). 2016;54(1):14-9. doi: 10.3109/15563650.2015.1101769. Clin Toxicol (Phila). 2016. PMID: 26653952
-
A New Differential Diagnosis: Synthetic Cannabinoids-Associated Acute Renal Failure.Methodist Debakey Cardiovasc J. 2015 Jul-Sep;11(3):189-91. doi: 10.14797/mdcj-11-3-189. Methodist Debakey Cardiovasc J. 2015. PMID: 26634029 Free PMC article. Review.
Cited by
-
CB1 Receptor Negative Allosteric Modulators as a Potential Tool to Reverse Cannabinoid Toxicity.Molecules. 2024 Apr 20;29(8):1881. doi: 10.3390/molecules29081881. Molecules. 2024. PMID: 38675703 Free PMC article.
-
Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists.Eur J Pharmacol. 2024 May 15;971:176549. doi: 10.1016/j.ejphar.2024.176549. Epub 2024 Mar 30. Eur J Pharmacol. 2024. PMID: 38561104 Free PMC article.
-
The impact of prenatal alcohol, synthetic cannabinoid and co-exposure on behavioral adaptations in adolescent offspring and alcohol self-administration in adulthood.Neurotoxicol Teratol. 2024 Mar-Apr;102:107341. doi: 10.1016/j.ntt.2024.107341. Epub 2024 Mar 14. Neurotoxicol Teratol. 2024. PMID: 38490565
-
New-Onset Prolonged Psychosis Following Synthetic Cannabinoid Use in an Older Patient: A Case Report.Psychopharmacol Bull. 2024 Mar 4;54(1):33-39. Psychopharmacol Bull. 2024. PMID: 38449474
-
Cannabidiol-Derived Cannabinoids: The Unregulated Designer Drug Market Following the 2018 Farm Bill.Med Cannabis Cannabinoids. 2024 Feb 13;7(1):10-18. doi: 10.1159/000536339. eCollection 2024 Jan-Dec. Med Cannabis Cannabinoids. 2024. PMID: 38352661 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical